BEZ235 (NVP-BEZ235, Dactolisib)

Catalog No.S1009

BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

Price Stock Quantity  
USD 110 In stock
USD 170 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

BEZ235 (NVP-BEZ235, Dactolisib) Chemical Structure

BEZ235 (NVP-BEZ235, Dactolisib) Chemical Structure
Molecular Weight: 469.55

Validation & Quality Control

Cited by 81 publications:

8 customer reviews :

Quality Control & MSDS

Related Compound Libraries

BEZ235 (NVP-BEZ235, Dactolisib) is available in the following compound libraries:

PI3K Inhibitors with Unique Features

Product Information

  • Compare PI3K
    Compare PI3K Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.
Targets p110α [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
mTOR (p70S6K) [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)

 View  More

IC50 4 nM 5 nM 6 nM 7 nM
In vitro BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. [1] BEZ235 is an mTORC1/2 catalytic inhibitor. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Trypanosoma brucei bruceiMVfBcpRqdWmlcn;ibYFtKEG|c3H5NUHW[oRNOThiaB?=MUfEUXNQNG\iXmpCdnSrdIL5dIFvd3OxbXHsJIFkfGm4aYT5JJdqfGhiRVO1NEBw\iByLkCwNlUh|ryPMoPMNlQ5ODV7NE[=
MCF7NGfYWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnoWolYOC5yMT2xNFAh|ryPM{jHflQ5KGh?MVnEUXNQMkW1TWM2OD1yLkezJO69VQ>?MlHtNlM5PzF7MES=
HCT116MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LPZVAvODFvMUCwJO69VQ>?NGLZeow1QCCqNILaVYpFVVORM1TZbWlEPTB;MT6xOkDPxE1?MmP2NlM5PzF7MES=
U87MGMnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\0fIZPOC5yMT2xNFAh|ryPM{fFXVQ5KGh?NWfU[2FwTE2VTx?=M3r2fGlEPTB;MT6zNkDPxE1?Mo\YNlM5PzF7MES=
HBC4NFHGb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHrO2UxNjBzLUGwNEDPxE1?M{DFNlQ5KGh?MkDaUI9oKEeLNUC9MVgvPjFiTR?=NXH2R49LOjJ|M{[yOFY>
BSY1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\FS|RSOC5yMT2xNFAh|ryPNIDoNZU1QCCqNX;EPYJlVG:pIFfJOVA:NThwNEigUS=>Mk\1NlI{OzZ{NE[=
HBC5MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TJVlAvODFvMUCwJO69VQ>?M{S3ZlQ5KGh?NWP4NpRCVG:pIFfJOVA:NTdwOEegUS=>NFu0eoUzOjN|NkK0Oi=>
MCF7MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvhdINkOC5yMT2xNFAh|ryPMVS0PEBpMonOUI9oKEeLNUC9MVgvOTZiTR?=MmHaNlI{OzZ{NE[=
MDA-MB-231NVzEfplTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY[wMlAyNTFyMDFOwG0>NHXhWYs1QCCqNHnIR5ZNd2diR1m1NF0uQC5yOTDNNYTGcIx3OjJ|M{[yOFY>
U251M2PpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHewfVQxNjBzLUGwNEDPxE1?NVr6TGE1PDhiaB?=MX\Mc4chT0l3ME2tO{43PiCPNELvXY4zOjN|NkK0Oi=>
SF268MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjTXW5POC5yMT2xNFAh|ryPNHTMbHk1QCCqMkC5UI9oKEeLNUC9MVcvQTJiTR?=NFrQSJczOjN|NkK0Oi=>
SF295NWqwbWJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYmwMlAyNTFyMDFOwG0>MWS0PEBpNYLH[Hl7VG:pIFfJOVA:NThwM{GgUS=>NH2yW4czOjN|NkK0Oi=>
SF539NV76cYpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnBTHUxNjBzLUGwNEDPxE1?NGrySXQ1QCCqMX3Mc4chT0l3ME2tPE42QSCPM4nPPVIzOzN4MkS2
SNB75NFzyW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXGwMlAyNTFyMDFOwG0>NXfpSnVDPDhiaB?=NEPFN2tNd2diR1m1NF0uQC53ODDNNUTwWZh[OjJ|M{[yOFY>
SNB78NWf5SY81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3FT|NTOC5yMT2xNFAh|ryPMk\DOFghcA>?MWXMc4chT0l3ME2tPE43PSCPNWX2XlRtOjJ|M{[yOFY>
HCC2998Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3P6SlAvODFvMUCwJO69VQ>?MnHnOFghcA>?Mn7nUI9oKEeLNUC9MVgvODViTR?=NVqyTmpnOjJ|M{[yOFY>
KM12NF6z[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVewMlAyNTFyMDFOwG0>M4LxVFQ5KGh?NUixb|hNVG:pIFfJOVA:NTdwNUSgUS=>NULOcpdiOjJ|M{[yOFY>
HT-29M{KxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\uZ|AvODFvMUCwJO69VQ>?MlO0OFghcA>?M1fDcmxw\yCJSUWwQU04Njd3IF2=MnuwNlI{OzZ{NE[=
HCT15M4Xx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjONE4xOS1zMECg{txOM1\MZ|Q5KGh?NV:2bYl4VG:pIFfJOVA:NThwMEOgUS=>MVKyNlM{PjJ2Nh?=
HCT116NF3Q[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmX5NE4xOS1zMECg{txONUXuNoQzPDhiaB?=M4nRb2xw\yCJSUWwQU04NjZzIF2=MW[yNlM{PjJ2Nh?=
NCI-H23MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;1SlJQOC5yMT2xNFAh|ryPNGPZ[Y41QCCqM3v6eGxw\yCJSUWwQU04NjZ2IF2=NVr1[Xl7OjJ|M{[yOFY>
NCI-H226MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXKwMlAyNTFyMDFOwG0>NVv5VINCPDhiaB?=NEe0bZVNd2diR1m1NF0uQC52NDDNNWTQOYl3OjJ|M{[yOFY>
NCI-H522MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTRTXcxNjBzLUGwNEDPxE1?NFK0UoU1QCCqM3\sfmxw\yCJSUWwQU05NjR3IF2=NWLmSlF5OjJ|M{[yOFY>
NCI-H438NIK1RoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13JT|AvODFvMUCwJO69VQ>?NU\yO5k5PDhiaB?=NFfEWJBNd2diR1m1NF0uQC5zMTDNM1LnSlIzOzN4MkS2
A549MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7BO5I5OC5yMT2xNFAh|ryPMXS0PEBpNICx[HlNd2diR1m1NF0uQC5yNzDNMn7HNlI{OzZ{NE[=
DMS273NFTocYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXvNE4xOS1zMECg{txONWTUXGNqPDhiaB?=NIDtTnZNd2diR1m1NF0uPy56MDDNMl;YNlI{OzZ{NE[=
DMS114MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX[wMlAyNTFyMDFOwG0>NFfwS5g1QCCqM3vlfGxw\yCJSUWwQU05NjN7IF2=MWKyNlM{PjJ2Nh?=
LOXIMVINXjOboNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV:wMlAyNTFyMDFOwG0>MYO0PEBpM4mxRWxw\yCJSUWwQU05NjZ4IF2=M1fEUVIzOzN4MkS2
OVCAR3NXnUWWZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYW2TG5bOC5yMT2xNFAh|ryPMlX6OFghcA>?NFfHWIxNd2diR1m1NF0uQC5zNzDNM3[5SFIzOzN4MkS2
OVCAR4NXT3bFFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWGyWXR1OC5yMT2xNFAh|ryPMn3XOFghcA>?NW[1dJV6VG:pIFfJOVA:NThwNUigUS=>MWOyNlM{PjJ2Nh?=
OVCAR5NHqwdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYC3cG9XOC5yMT2xNFAh|ryPMYC0PEBpMl7SUI9oKEeLNUC9MVcvPTdiTR?=NI\FT40zOjN|NkK0Oi=>
OVCAR8M2P5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVywMlAyNTFyMDFOwG0>NEjRNJo1QCCqM4TRdmxw\yCJSUWwQU04Njh2IF2=MmTGNlI{OzZ{NE[=
SKOV3M13Q[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF60TZgxNjBzLUGwNEDPxE1?M3nyWVQ5KGh?MljRUI9oKEeLNUC9MVgvPDFiTR?=M2jqZVIzOzN4MkS2
RXF631LM{TMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zwZlAvODFvMUCwJO69VQ>?NUHJdHl[PDhiaB?=NF3iPGxNd2diR1m1NF0uQC5{MTDNMkPxNlI{OzZ{NE[=
ACHNNGD0NYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnroNE4xOS1zMECg{txOMYO0PEBpNF\rdYRNd2diR1m1NF0uPy57NTDNMW[yNlM{PjJ2Nh?=
St-4M3TTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIr1WHQxNjBzLUGwNEDPxE1?MXi0PEBpNVOwNpI{VG:pIFfJOVA:NTdwNEegUS=>M1f6bVIzOzN4MkS2
MKN1NVfKRmV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV6wMlAyNTFyMDFOwG0>M{jIXFQ5KGh?NGT5VIFNd2diR1m1NF0uQC52MTDNNXHFZ2U6OjJ|M{[yOFY>
MKN7NHLjcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\NNE4xOS1zMECg{txOMn3rOFghcA>?M3KzRWxw\yCJSUWwQU04NjZ6IF2=MmfXNlI{OzZ{NE[=
MKN28MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrDNE4xOS1zMECg{txONWjLR2xSPDhiaB?=M1LM[Wxw\yCJSUWwQU04NjB5IF2=MXiyNlM{PjJ2Nh?=
MKN45Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPwWZkxNjBzLUGwNEDPxE1?MofqOFghcA>?M1\acWxw\yCJSUWwQU05NjN2IF2=NGDmPZIzOjN|NkK0Oi=>
MKN74MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzBbncxNjBzLUGwNEDPxE1?NXLKd3B{PDhiaB?=NVzjPGM6VG:pIFfJOVA:NTdwNEKgUS=>M1Wx[lIzOzN4MkS2
DU145MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fFVlAvODFvMUCwJO69VQ>?NYPvSFVTPDhiaB?=M3;vUmxw\yCJSUWwQU05NjF4IF2=MX:yNlM{PjJ2Nh?=
PC3NWHrPGdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\pVVAvODFvMUCwJO69VQ>?NH7FcmE1QCCqM3Oydmxw\yCJSUWwQU05NjZ4IF2=M2fX[lIzOzN4MkS2
Trypanosoma brucei bruceiMmDoSpVv[3Srb36gRZN{[Xl?NVLEV5EzOjByIH7NMV[xNkBpMULEUXNQMlPrSIVkemWjc3WgbY4heGixc4Doc5Rq\HmuIHnuc5NqfG:uIIDoc5NxcGG2ZTDs[ZZmdA>?NXPkTnZROjR6MEW5OFY>
Trypanosoma brucei bruceiNUfvRpE1TnWwY4Tpc44hSXO|YYm=NHzIcYUyQCCqNITWT4RFVVORNIXsUJRKdmirYnn0bY9vKG:oIILlZ4VxfG:{LX3l[IlifGWmIHXu[I9kgXSxc3nzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIITyZY5{\mW{cnnuJJVxfGGtZR?=NU\wRXhYOjR6MEW5OFY>
Trypanosoma brucei bruceiMU\GeY5kfGmxbjDBd5NigQ>?MXGyNFAhdk1?MmPkNVIhcA>?MmDySG1UVw>?MX\F[oZm[3Rib36gd5BpcW6pb335cIVqdiCuZY\lcC=>NGO3PYszPDhyNUm0Oi=>
Trypanosoma brucei bruceiM2jOXGZ2dmO2aX;uJGF{e2G7MlPLNlAxKG6PM{PBOFEzKGh?MYrEUXNQNEGzWHZG\m[nY4Sgc44heGixc4DoZZRq\HmuY3jvcIlv\SCuZY\lcC=>MWGyOFgxPTl2Nh?=
UM-UC-3M1fC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{i4NWlEPTB;M{G1JJBONEHRNlhUSU6JRWK=
SBC-1NW\UOJFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlX5TWM2OD15NEKgdG0>M4D2PXNCVkeHUh?=
MKN1NULZcI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHxO4JsUUN3ME2yMlghdk1?MUnTRW5ITVJ?
NCI-H720NG\mRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTNwNUegcm0>Mk\4V2FPT0WU
BFTC-909NHuyWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDEW25oUUN3ME2zMlcyKG6PNFruV2hUSU6JRWK=
BPH-1MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfiT3hSUUN3ME20Mlc3KG6PNGnxUWdUSU6JRWK=
PC-3MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTVwMEmgcm0>MmrCV2FPT0WU
AN3-CAMkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfab|ZKSzVyPUWuOVYhdk1?NGr1[opUSU6JRWK=
HNM1rncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4X5d2lEPTB;NT65OkBvVQ>?MUTTRW5ITVJ?
HCC2218MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\D[nVHUUN3ME22MlYyKG6PM2jpPXNCVkeHUh?=
KP-4MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvmSotKSzVyPUegcm0>NH3XSFdUSU6JRWK=
LU-139M3TUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nmfWlEPTB;Nz63O{BvVQ>?NYX1ZXVkW0GQR1XS
ETK-1M4PQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEW5bldKSzVyPUeuPFghdk1?NYD1d3lPW0GQR1XS
Ramos-2G6-4C10NF;ueo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRThwNEmgcm0>NV\3WmRrW0GQR1XS
MHH-PREB-1M1r2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTlwMUKgcm0>NW\IbYU{W0GQR1XS
DU-4475NEnpbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XDVGlEPTB;OT60OEBvVQ>?MWfTRW5ITVJ?
NCI-H1666NUfCVJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTlwN{Ggcm0>NF7EO3pUSU6JRWK=
CAMA-1NVm3V3lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGT3dYRKSzVyPUmuPEBvVQ>?MnjjV2FPT0WU
TYK-nuM{PlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTlwOUSgcm0>NH3pdnlUSU6JRWK=
MFE-280NVuxdlY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVP3SHZMUUN3ME25Mlk6KG6PM3TiTHNCVkeHUh?=
A549M4rPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTFyLkG0JI5ONIDkT4RUSU6JRWK=
769-PNXLNTIkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\uUplKSzVyPUGwMlQ1KG6PNFn1VJJUSU6JRWK=
L-363MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTFyLk[5JI5OMWTTRW5ITVJ?
ES8M{DDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vlSGlEPTB;MUCuPUBvVQ>?M4LDWHNCVkeHUh?=
PA-1M1:4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vacmlEPTB;MUGuPFIhdk1?NFTTTIFUSU6JRWK=
MewoNGDCR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LUdmlEPTB;MUGuPVkhdk1?Mor1V2FPT0WU
HSC-3MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXMcIlKSzVyPUGyMlIyKG6PNEDFc3lUSU6JRWK=
H4NGS0elBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1Xke2lEPTB;MUKuOlchdk1?MWjTRW5ITVJ?
BB65-RCCMkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXNWVFKSzVyPUGyMlczKG6PNV3tV48xW0GQR1XS
NCI-H1793NFL1NpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTF{LkiyJI5ONGjlZZdUSU6JRWK=
KARPAS-45NVjRSmFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHhTVl7UUN3ME2xN{42OSCwTR?=NVfE[4ZqW0GQR1XS
GCTMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnNZ3FKSzVyPUGzMlY5KG6PMYTTRW5ITVJ?
EoL-1Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7rTWM2OD1zMz65N{BvVQ>?MXXTRW5ITVJ?
LB2241-RCCM{nLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTF2LkCxJI5ONXTEVGFCW0GQR1XS
ES5NEjTPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEGwfXZKSzVyPUG0Mlc1KG6PMmX0V2FPT0WU
LOXIMVIMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkm2TWM2OD1zND65PUBvVQ>?Mn75V2FPT0WU
COR-L105NG\uR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;GWoFKSzVyPUG1MlA1KG6PMXLTRW5ITVJ?
P12-ICHIKAWANFXIb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojWTWM2OD1zNT6xJI5OMYTTRW5ITVJ?
CHL-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfZR2NQUUN3ME2xOU41PSCwTR?=NWfuTGxpW0GQR1XS
VMRC-RCZMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjrSWhKSzVyPUG1MlY{KG6PM2X5THNCVkeHUh?=
HHM3T0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXHXFVKSzVyPUG1Mlchdk1?MWTTRW5ITVJ?
NUGC-3NWKzSmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTqSHNKSzVyPUG2MlM1KG6PNX7PTXV[W0GQR1XS
EGI-1M{\CUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTF4LkSzJI5OMWjTRW5ITVJ?
OS-RC-2MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfmeI9RUUN3ME2xOk41PyCwTR?=NEjCOodUSU6JRWK=
MOLT-16NHjXV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XrUGlEPTB;MUeuNVUhdk1?M1POOXNCVkeHUh?=
NCI-H209NX31RlloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NESwNJNKSzVyPUG3MlI6KG6PMULTRW5ITVJ?
697MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mor6TWM2OD1zNz60N{BvVQ>?M2LpT3NCVkeHUh?=
D-56MGNHXRN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PEPWlEPTB;MUeuOlkhdk1?NYDMRXc1W0GQR1XS
VA-ES-BJM1f1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDFenJKSzVyPUG3Mlg{KG6PNHLrcldUSU6JRWK=
EW-16M2D6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13qTWlEPTB;MUiuNFQhdk1?NUDMSWJ3W0GQR1XS
HGC-27MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTF6LkC2JI5OM3mxSnNCVkeHUh?=
ES7MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\PXlE2UUN3ME2xPE4xQSCwTR?=NFnLZo9USU6JRWK=
HuH-7MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPtTZFKSzVyPUG4MlQhdk1?NELOTlRUSU6JRWK=
BCPAPMoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTF6Lk[1JI5OMmHSV2FPT0WU
SW1710M{DTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXFN3hKSzVyPUG4MlczKG6PMnrqV2FPT0WU
IST-MEL1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULyWZJMUUN3ME2xPE44PyCwTR?=NE\JVW1USU6JRWK=
SF295MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnETWM2OD1zOD65N{BvVQ>?NGmwZ5lUSU6JRWK=
RPMI-7951MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XtdWlEPTB;MUmuNlghdk1?M1PyT3NCVkeHUh?=
SF126M1XLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTF7LkSxJI5OMU\TRW5ITVJ?
GAMGM3Ps[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXDcG17UUN3ME2xPU41QCCwTR?=MkXCV2FPT0WU
KNS-81-FDMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nKPWlEPTB;MUmuOVQhdk1?NXjaZ4tXW0GQR1XS
RT-112Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWj4[244UUN3ME2xPU43PiCwTR?=MlzEV2FPT0WU
DELNXPQWIxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLvO29YUUN3ME2yNE41QSCwTR?=M4[3c3NCVkeHUh?=
CGTH-W-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrxTWM2OD1{MD62N{BvVQ>?MlnGV2FPT0WU
HOSMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HCXmlEPTB;MkGuNFYhdk1?MUDTRW5ITVJ?
ES4NVXMW|k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLWWIVxUUN3ME2yNU4xQCCwTR?=MWXTRW5ITVJ?
RXF393M1vNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrnT2JKSzVyPUKxMlQ2KG6PMXjTRW5ITVJ?
NCI-H2030MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTJzLkWyJI5ONHS5UpFUSU6JRWK=
YH-13NV;3XlM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILab|VKSzVyPUKxMlg5KG6PNGrsTphUSU6JRWK=
HT-1080NIPmdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGj1WJJKSzVyPUKxMlk{KG6PMVjTRW5ITVJ?
NCI-SNU-1NF3QVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrqS|FKSzVyPUKxMlk2KG6PNYn5PYZSW0GQR1XS
G-402MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljRTWM2OD1{Mj6xOkBvVQ>?MUjTRW5ITVJ?
786-0NVz6NlhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULiWFlLUUN3ME2yNk4zQSCwTR?=NHfjT4RUSU6JRWK=
ME-180M4TKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTJ{LkSzJI5ONYK2PGxXW0GQR1XS
NB69NY\Yfod7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGX2TYhKSzVyPUKyMlU{KG6PMWXTRW5ITVJ?
J-RT3-T3-5M2DqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PpWmlEPTB;MkKuPVYhdk1?MoqyV2FPT0WU
TGBC1TKBMkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorhTWM2OD1{Mz6wOUBvVQ>?NInCT5lUSU6JRWK=
SW780NV:1ZWNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fqWmlEPTB;MkOuNVMhdk1?NIm1R5dUSU6JRWK=
MG-63M130Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXpN5VKSzVyPUKzMlQ2KG6PMX\TRW5ITVJ?
BV-173Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTJ|Lki3JI5ONG\TZ5FUSU6JRWK=
CAL-51MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnP[|lKSzVyPUKzMlg6KG6PM2HFdHNCVkeHUh?=
A375M2PsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\hUWNzUUN3ME2yN{46OyCwTR?=M1naW3NCVkeHUh?=
MEL-HONYfmW|ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;sNYdzUUN3ME2yOE4xPCCwTR?=NWHEOJhoW0GQR1XS
EFO-27MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTJ2LkOzJI5ONFzvS4FUSU6JRWK=
Hs-578-TM1LP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\GV4RKSzVyPUK0MlU5KG6PMkXDV2FPT0WU
NBsusSRM1fBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;oR4VKSzVyPUK0MlYhdk1?M2W1[HNCVkeHUh?=
CTB-1NVT4WIpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjQSXVrUUN3ME2yOE43PyCwTR?=NUO4SlJMW0GQR1XS
FTC-133NX3rcIZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJ3LkGgcm0>NUS0cWh[W0GQR1XS
MOLT-4MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nJXWlEPTB;MkWuNVIhdk1?M4PNZnNCVkeHUh?=
HO-1-N-1MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXUU3JKSzVyPUK1MlE2KG6PNWLhT5ozW0GQR1XS
ES3M2fu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX:zRodSUUN3ME2yOU4zOiCwTR?=MUTTRW5ITVJ?
TI-73M4XrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTJ3LkK4JI5ONW\Nbo57W0GQR1XS
MPP-89NYHCU3dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2npfWlEPTB;MkWuN|Ihdk1?MkntV2FPT0WU
KYSE-150NYW4cnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfidFJtUUN3ME2yOU45QSCwTR?=MWjTRW5ITVJ?
LXF-289MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoL1TWM2OD1{Nj6wOEBvVQ>?MYTTRW5ITVJ?
SK-LU-1M325fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{G1e2lEPTB;Mk[uNVchdk1?MYLTRW5ITVJ?
HOP-92MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTqcINQUUN3ME2yOk41QCCwTR?=NIrsO4pUSU6JRWK=
HuO9NHLtPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmL4TWM2OD1{Nj63OkBvVQ>?NV;mdWpIW0GQR1XS
SW962MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\OTWM2OD1{Nj63OkBvVQ>?MWnTRW5ITVJ?
RS4-11NYPnVFM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;KZ2lEPTB;Mk[uPVEhdk1?M1HLcHNCVkeHUh?=
NCI-H292MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDRTWM2OD1{NzDuUS=>M2LD[nNCVkeHUh?=
DBNIXLUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLrVpVKSzVyPUK3MlM3KG6PNWnlNpc5W0GQR1XS
SW1088MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;oeGN[UUN3ME2yPE4zQSCwTR?=MkS5V2FPT0WU
A204M2TrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnK4TWM2OD1{OD60O{BvVQ>?M2LqS3NCVkeHUh?=
A3-KAWMlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF33fXFKSzVyPUK4MlY1KG6PMWTTRW5ITVJ?
MV-4-11NIjFXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJ6Lkegcm0>NUH2OopCW0GQR1XS
ES1NWjWd4t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTJ6Lki0JI5ONYjHbVV6W0GQR1XS
ONS-76NGLSe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjPdZhKSzVyPUK5MlA2KG6PNGnCZ4RUSU6JRWK=
D-263MGMn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjWTGxKSzVyPUK5MlM2KG6PMYLTRW5ITVJ?
U-2-OSNVK5OZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHGTWM2OD1{OT61JI5ONVHKSodxW0GQR1XS
T98GMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fTNWlEPTB;MkmuPFghdk1?NF\UVmpUSU6JRWK=
GI-ME-NMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\yV2lEPTB;MkmuPVEhdk1?Ml\DV2FPT0WU
BHT-101NFvWTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPOV3FOUUN3ME2zNE4xPSCwTR?=NH;SOYpUSU6JRWK=
NOS-1NF;TdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;ETWM2OD1|MD6xNkBvVQ>?NVzLUZdDW0GQR1XS
AsPC-1Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnm5TWM2OD1|MD6yJI5ONI\EdndUSU6JRWK=
QIMR-WILNWrWcpAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTNyLk[gcm0>MnK2V2FPT0WU
JVM-3NUnicYRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPxTm9KSzVyPUOwMlg{KG6PM1;L[3NCVkeHUh?=
KU-19-19NUP0SIxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3pTWM2OD1|MT6xN{BvVQ>?NGTtcpRUSU6JRWK=
OVCAR-8NXnLVWN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7RXmRKSzVyPUOxMlI3KG6PNV65XZdmW0GQR1XS
BENM1XZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDGTWM2OD1|MT62N{BvVQ>?NFTjfHRUSU6JRWK=
BE-13Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTNzLkiyJI5OMl;oV2FPT0WU
EW-18NVHXRlg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfPWoZKSzVyPUOxMlg3KG6PMnjBV2FPT0WU
ECC10NHPKUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXoVI1KSzVyPUOxMlk2KG6PM1m2eXNCVkeHUh?=
CTV-1M4jDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHCS4hlUUN3ME2zNk45OiCwTR?=MYrTRW5ITVJ?
COLO-800NYXXdmtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\OVYRbUUN3ME2zNk46OiCwTR?=MWnTRW5ITVJ?
A2058NIXiUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTN|LkK1JI5OMojjV2FPT0WU
VM-CUB-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHuz[G1KSzVyPUOzMlQ{KG6PM1fvenNCVkeHUh?=
Ca9-22M3[xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjETWM2OD1|Mz61OUBvVQ>?MUDTRW5ITVJ?
COLO-684M1voNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fLSGlEPTB;M{OuOVghdk1?NGLqUVRUSU6JRWK=
RPMI-8226M{TVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTN|LkiyJI5OM4TofnNCVkeHUh?=
SK-NEP-1NGGxe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1qxWWlEPTB;M{SuNVUhdk1?Mnv3V2FPT0WU
BeckerNWPvO5hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTN2LkKxJI5OM{i3NXNCVkeHUh?=
NCI-H28MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVeybGNuUUN3ME2zOE41PCCwTR?=MnPpV2FPT0WU
CAL-120NHzUd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTN2LkeyJI5ONV;BTVNxW0GQR1XS
MDA-MB-157MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYL5NmI5UUN3ME2zOU41OSCwTR?=NX;hN4NWW0GQR1XS
OVCAR-5NWO1SZFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTN3LkS3JI5OM{LKbHNCVkeHUh?=
LAMA-84M{HzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDMTWM2OD1|NT64O{BvVQ>?NH;heIdUSU6JRWK=
CAKI-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XBZWlEPTB;M{[uOFMhdk1?NVr6NHpHW0GQR1XS
DaoyMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvCTpRKSzVyPUO2Mlchdk1?Ml;6V2FPT0WU
CAL-62MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTN4Lki2JI5ONUXiTohKW0GQR1XS
8-MG-BAMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3XTWM2OD1|Nz6yOUBvVQ>?NHXq[nRUSU6JRWK=
8505CM3XoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGH0OIVKSzVyPUO3MlUyKG6PM4fzcXNCVkeHUh?=
LNCaP-Clone-FGCM1rrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTITWM2OD1|Nz61PUBvVQ>?MkLFV2FPT0WU
CAL-39NGPT[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPx[VJKSzVyPUO3Mlkhdk1?MYTTRW5ITVJ?
MN-60M{jBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTN5Lkm2JI5OMYLTRW5ITVJ?
RKONVPybWdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVr1T3J3UUN3ME2zPE4{OyCwTR?=M4LtcnNCVkeHUh?=
U251M{DOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTN6LkSzJI5ONGPlZmNUSU6JRWK=
SJSA-1Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PXR2lEPTB;M{iuOVQhdk1?MYjTRW5ITVJ?
CAL-12TMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELueY9KSzVyPUO4MlYhdk1?NWmzTYU3W0GQR1XS
HCC1419NYDYVHNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTN6LkexJI5ONUDJeodNW0GQR1XS
CO-314MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TUOGlEPTB;M{iuO|Qhdk1?MVXTRW5ITVJ?
LB1047-RCCM4S2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLLTmxKSzVyPUO4MlgyKG6PM{HLcnNCVkeHUh?=
A101DM{ns[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mke4TWM2OD1|OD65O{BvVQ>?NXLRT5B[W0GQR1XS
MDA-MB-175-VIIM1\TOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTIU2hEUUN3ME2zPU42OSCwTR?=MVXTRW5ITVJ?
MZ2-MELNUjYZpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDndnBKSzVyPUO5MlY3KG6PMUXTRW5ITVJ?
NB5NVfmRVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTRyLk[0JI5OMUXTRW5ITVJ?
G-401NHHtNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTEb4VKSzVyPUSwMlgzKG6PNFviZ4dUSU6JRWK=
HTMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDKcIhKSzVyPUSxMlAzKG6PNHvzbYNUSU6JRWK=
8305CMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTRzLki3JI5ONIfTWXFUSU6JRWK=
BHYMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTR{LkeyJI5OM3z6OnNCVkeHUh?=
NTERA-S-cl-D1M4Hhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1W2SGlEPTB;NEOgcm0>NICw[5VUSU6JRWK=
T-24NHPoZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PtTWlEPTB;NEOuPFMhdk1?NHewbpZUSU6JRWK=
EPLC-272HNU[wfWJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjJVFlKSzVyPUS0MlM6KG6PNVfpUnM1W0GQR1XS
PSN1M{nFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGD6d25KSzVyPUS0MlQhdk1?MnXHV2FPT0WU
NCI-H2452NILFfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmX6TWM2OD12ND61PEBvVQ>?MYTTRW5ITVJ?
KS-1NXfKUHpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTR2Lk[2JI5ONUHXRoVSW0GQR1XS
HD-MY-ZNE\RN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvneZluUUN3ME20OE46OiCwTR?=NFfMR2RUSU6JRWK=
KNS-62NYLTV3Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlKzTWM2OD12NT6zPEBvVQ>?NHTSbVNUSU6JRWK=
NOMO-1M1nlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnjTWM2OD12NT64O{BvVQ>?M1LVVHNCVkeHUh?=
SK-HEP-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTR4LkC0JI5ONFLhZpBUSU6JRWK=
IGR-1Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmX5TWM2OD12Nj6xN{BvVQ>?MUXTRW5ITVJ?
KYSE-180MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HYOGlEPTB;NE[uNVchdk1?MXjTRW5ITVJ?
EW-22NXzEeYhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHFTWM2OD12Nj6yJI5OM4G1SXNCVkeHUh?=
NCI-H1355NUHTb3RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTR4LkO0JI5ONY\5dFkyW0GQR1XS
DOHH-2Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXrTWM2OD12Nj6zO{BvVQ>?NET6T|JUSU6JRWK=
A4-FukMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3z6[mlEPTB;NE[uOVIhdk1?NHLicI1USU6JRWK=
PC-14NXG5dJFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTR4LkW3JI5OMk\oV2FPT0WU
TE-5NVHacpZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DFVGlEPTB;NE[uPFQhdk1?NEPySHdUSU6JRWK=
LB996-RCCNV3VeWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LrT2lEPTB;NEeuNVkhdk1?MXXTRW5ITVJ?
NCI-H1623MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fUd2lEPTB;NEeuO|Yhdk1?MYfTRW5ITVJ?
NCI-H1155NY\nOFhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXXZVdSUUN3ME20PE4{OiCwTR?=NX70N5RMW0GQR1XS
LoVoNED1XnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTR6LkSgcm0>NIDuS4hUSU6JRWK=
MCF7NV7UemFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTR6LkW4JI5ONEnFc2tUSU6JRWK=
AGSMl[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\wcldKSzVyPUS4Mlc4KG6PNVTOVoYxW0GQR1XS
PFSK-1NHzqe|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTR7LkC2JI5OMWXTRW5ITVJ?
22RV1M17uSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVH1VmRxUUN3ME20PU4xQSCwTR?=MXHTRW5ITVJ?
COR-L23MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkGxTWM2OD12OT6xOkBvVQ>?M1XQcXNCVkeHUh?=
D-283MEDNFH0[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnq1TWM2OD12OT62NUBvVQ>?M2PNNXNCVkeHUh?=
SW982NEfw[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWX0RW1MUUN3ME20PU46OSCwTR?=M4LRfnNCVkeHUh?=
SW620Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;jPZVKSzVyPUWwMlM3KG6PMkLNV2FPT0WU
KYSE-140MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jW[2lEPTB;NUCuOVUhdk1?NV\UPVQ4W0GQR1XS
GCIYMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonQTWM2OD13MD62O{BvVQ>?NGT4VGFUSU6JRWK=
MHH-ESS-1NYfG[IppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjKTWM2OD13MT65OUBvVQ>?MW\TRW5ITVJ?
D-423MGNVq3eW1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HC[mlEPTB;NUKuNFghdk1?NYL6XYt[W0GQR1XS
SF539NETpc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnUcHJDUUN3ME21Nk4{PSCwTR?=MmjZV2FPT0WU
RPMI-2650M4O2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjEdpVlUUN3ME21Nk43QSCwTR?=M1LrU3NCVkeHUh?=
GR-STNIS1fppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkW3TWM2OD13Mj64O{BvVQ>?M2rseXNCVkeHUh?=
YKG-1MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rRW2lEPTB;NUOgcm0>M2rlUHNCVkeHUh?=
SK-MES-1NGnUNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWP5WHhqUUN3ME21N{4zPiCwTR?=NWn4WYtzW0GQR1XS
HLEM2m4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEf1dZVKSzVyPUWzMlQ4KG6PNX7qb2RtW0GQR1XS
RVH-421NX\WT2p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDycGdVUUN3ME21N{43PyCwTR?=MWLTRW5ITVJ?
C32NELoWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\BN4dXUUN3ME21N{45OyCwTR?=MWnTRW5ITVJ?
GB-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXYTWM2OD13ND6yJI5OM333XnNCVkeHUh?=
SNB75NXW1[HhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7aTWM2OD13ND6yOkBvVQ>?MUTTRW5ITVJ?
EM-2Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTV2LkSgcm0>MljZV2FPT0WU
RH-1MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTV2Lkegcm0>NYe2RpVFW0GQR1XS
NKM-1NV;WdXh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILQXpdKSzVyPUW0MlgyKG6PNWfjNopKW0GQR1XS
NCI-H2405MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEOySnhKSzVyPUW0Mlg5KG6PNYWwPYVDW0GQR1XS
KYSE-450NVT6VIpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTQdmFkUUN3ME21OU4yPiCwTR?=MYnTRW5ITVJ?
A704M3qxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jjemlEPTB;NUWuOVkhdk1?M{TPc3NCVkeHUh?=
HAL-01MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTV3LkizJI5ONIGzU4pUSU6JRWK=
TE-11NXTCS|E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3hfndKSzVyPUW1Mlk6KG6PMlnlV2FPT0WU
DOKM4rqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nvUWlEPTB;NU[uNFIhdk1?MoTlV2FPT0WU
KY821M4D0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\wOVRVUUN3ME21Ok4zKG6PNF;kSVNUSU6JRWK=
KGNMmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4W2b2lEPTB;NU[uN|Ihdk1?MX3TRW5ITVJ?
MC116M2HHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTV5Lkigcm0>MY\TRW5ITVJ?
PANC-08-13NVzCfIp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXf4W5BuUUN3ME21PE4xOSCwTR?=MorGV2FPT0WU
KE-37MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4C2WWlEPTB;NUiuO|chdk1?M2rQcnNCVkeHUh?=
KYSE-410M4nvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTV7LkS3JI5ONYPHS3BMW0GQR1XS
RO82-W-1MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUT4ZW5ZUUN3ME21PU46KG6PMk\BV2FPT0WU
M14MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7aVWJKSzVyPU[wMlA1KG6PNEPQN4pUSU6JRWK=
GI-1MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTZyLkOgcm0>M{e2bXNCVkeHUh?=
ML-2NH\HO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnVT4VVUUN3ME22NE43OiCwTR?=M2POVnNCVkeHUh?=
BFTC-905MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUK2W5NJUUN3ME22NE43PSCwTR?=MUHTRW5ITVJ?
DMS-273NGj6e5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7LTlZYUUN3ME22NE45PyCwTR?=MWDTRW5ITVJ?
MDA-MB-361MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3CTWM2OD14MTDuUS=>MWXTRW5ITVJ?
MSTO-211HNVvKcXNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mom1TWM2OD14Mz61NUBvVQ>?MYrTRW5ITVJ?
MEG-01MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDwRWFKSzVyPU[zMlUzKG6PM{j4c3NCVkeHUh?=
M059JMmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTZ|LkW4JI5OMWPTRW5ITVJ?
LN-405MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLZfplrUUN3ME22N{45PSCwTR?=MUnTRW5ITVJ?
NCI-H1581NIHneINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn76TWM2OD14ND6wN{BvVQ>?NYHJU5FvW0GQR1XS
TCCSUPMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmH3TWM2OD14ND61N{BvVQ>?M1PRe3NCVkeHUh?=
SW872MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\nTWM2OD14ND61O{BvVQ>?MXfTRW5ITVJ?
KYSE-510M2jOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYr6e3UyUUN3ME22OU44PSCwTR?=MWDTRW5ITVJ?
NCI-H1792MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTZ4LkG1JI5OM4HhcnNCVkeHUh?=
SW13MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDqdGpKSzVyPU[2MlUhdk1?M2\ZO3NCVkeHUh?=
TE-8Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7HTWM2OD14Nj61NkBvVQ>?NF[0[|lUSU6JRWK=
SCHNITPbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTZ5LkGgcm0>M33uUXNCVkeHUh?=
NEC8MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoO5TWM2OD14Nz6yOEBvVQ>?MVfTRW5ITVJ?
HuO-3N1MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XwUWlEPTB;NkeuN|Ehdk1?MWTTRW5ITVJ?
EFM-19MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHGU5JKSzVyPU[3MlUhdk1?M4XhN3NCVkeHUh?=
HEC-1NYjxSJprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVO0[FliUUN3ME22O{42OiCwTR?=NGDkWGJUSU6JRWK=
T47DMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTZ5Lki3JI5ONEf2S2RUSU6JRWK=
SNU-423Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTZ5Lkm4JI5OMVPTRW5ITVJ?
WM-115MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjmS5hKSzVyPU[4MlE1KG6PMX\TRW5ITVJ?
CaR-1NIPEOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTZ6LkK1JI5OMXLTRW5ITVJ?
KU812MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTZ6Lk[5JI5ONIDFeY5USU6JRWK=
AM-38MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPMTWM2OD14OT6zNUBvVQ>?M37jbXNCVkeHUh?=
KOSC-2MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33ndmlEPTB;NkmuPVchdk1?NVj0V|ljW0GQR1XS
MC-IXCM3P1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjRO2xMUUN3ME23NE4xQCCwTR?=M2XIcHNCVkeHUh?=
SCC-4M2KwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPIT3VNUUN3ME23NU4{QCCwTR?=NVrLOnVuW0GQR1XS
Calu-3MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXL4NmF6UUN3ME23NU46QCCwTR?=NVPHRnA3W0GQR1XS
RPMI-8866NHex[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnn5TWM2OD15Mj64NkBvVQ>?NIL5bYFUSU6JRWK=
OVCAR-4MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTd|LkO2JI5ONHXCfFlUSU6JRWK=
OAW-42M3LH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTd|LkO5JI5OMX\TRW5ITVJ?
ATN-1MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jLSmlEPTB;N{OuPFchdk1?NV\o[JN1W0GQR1XS
CHP-212NX\m[ldjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXaTWM2OD15ND65OUBvVQ>?MkfnV2FPT0WU
C2BBe1M{DpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3j1N2lEPTB;N{WuNFMhdk1?MkD4V2FPT0WU
A498MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1n3ZWlEPTB;N{WuNVUhdk1?M4LFd3NCVkeHUh?=
SH-4MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTd3LkKxJI5OM4O5[nNCVkeHUh?=
SNU-449NELLfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fNcGlEPTB;N{WuO|khdk1?NGjMUFZUSU6JRWK=
RDM1jmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTnTWM2OD15NT64OkBvVQ>?MoTBV2FPT0WU
PANC-03-27M37uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\yTWM2OD15Nj6yOUBvVQ>?MWXTRW5ITVJ?
S-117NWm0OJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3zRm9KSzVyPUe2MlI4KG6PNF64W2NUSU6JRWK=
SK-MEL-2Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;K[GJqUUN3ME23Ok44PSCwTR?=M1vTN3NCVkeHUh?=
LK-2NYfDbXd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3jTWM2OD15Nz6wOUBvVQ>?NGiwW2FUSU6JRWK=
CP50-MEL-BMnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzyTWhKSzVyPUe3MlQhdk1?M{XXfnNCVkeHUh?=
647-VMoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfGXIZqUUN3ME23PE4xPyCwTR?=MmPGV2FPT0WU
LU-134-ANYDNPIM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7zOmdMUUN3ME23PU4xOyCwTR?=M4jjbHNCVkeHUh?=
5637M4DwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTd7LkKzJI5OMnPwV2FPT0WU
NCI-H1437NELtOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRThyLkWgcm0>NGjFb49USU6JRWK=
NCI-H460NHTWV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\xNmlEPTB;OEGuNlMhdk1?MV\TRW5ITVJ?
BxPC-3MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRThzLkS2JI5OMkf2V2FPT0WU
CANMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRThzLki0JI5ONVvqVoc5W0GQR1XS
KINGS-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHWd4NKSzVyPUiyMlMzKG6PNEO4WZBUSU6JRWK=
OCUB-MNWnITVl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkL3TWM2OD16Mj60NUBvVQ>?M2ryd3NCVkeHUh?=
KALS-1MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PwT2lEPTB;OEKuOVQhdk1?NU[5fFdOW0GQR1XS
OCI-AML2M1XWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfHZ4pKSzVyPUiyMlYyKG6PMW\TRW5ITVJ?
A253NUPle25vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfYcGdFUUN3ME24Nk43PSCwTR?=MVnTRW5ITVJ?
LCLC-97TM1NIX0OGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PpbWlEPTB;OEKuPFYhdk1?MlfiV2FPT0WU
NCI-H520Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnDTWM2OD16Mz6wOkBvVQ>?MXvTRW5ITVJ?
P30-OHKNF7Fc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmX5TWM2OD16Mz61JI5ONE\Ed5JUSU6JRWK=
SBC-5NIP2dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nFTGlEPTB;OEOuOVIhdk1?NFvCU3pUSU6JRWK=
HCE-TMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rsd2lEPTB;OEOuO|Qhdk1?M{HkcHNCVkeHUh?=
JEG-3MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTh2LkGgcm0>NEL3TGlUSU6JRWK=
KG-1NVj6dYViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTh2LkK0JI5OM4PUbXNCVkeHUh?=
MIA-PaCa-2MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX75PWh[UUN3ME24OE42PCCwTR?=MVvTRW5ITVJ?
CAL-33NFy2bYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nyRmlEPTB;OEWuNFghdk1?NXjRd|FtW0GQR1XS
639-VMlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTh3LkSyJI5ONYfo[m1ZW0GQR1XS
NCI-H1048NXvZPWV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnVTWM2OD16Nj6zNUBvVQ>?M4XWZnNCVkeHUh?=
NCI-H1573NIPLfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jvdWlEPTB;OEeuOFghdk1?NHrsSHNUSU6JRWK=
NCI-H2228MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTh6LkK2JI5OMkjWV2FPT0WU
NB14MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTh6LkOgcm0>MYrTRW5ITVJ?
SCC-25MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{WwOmlEPTB;OEmuPFIhdk1?MYLTRW5ITVJ?
A431MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGq4VFJKSzVyPUi5Mlk4KG6PMlH0V2FPT0WU
SN12CM2H5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTlyLk[yJI5ONWDEbZBtW0GQR1XS
HuCCT1M17WXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3hSI9KSzVyPUmwMlc3KG6PM{m5OnNCVkeHUh?=
LS-123M1y4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjuVJhlUUN3ME25Nk4yQCCwTR?=MX\TRW5ITVJ?
CAL-85-1NXXjZ4xMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2O5VmlEPTB;OUKuOFghdk1?MkfxV2FPT0WU
ES6NEnIPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX[0V|NjUUN3ME25Nk45OyCwTR?=NV25c29RW0GQR1XS
NCI-H650MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIiwcWVKSzVyPUm0MlA6KG6PM{DHZXNCVkeHUh?=
NCI-H446MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoniTWM2OD17NT6xNkBvVQ>?M{LkbnNCVkeHUh?=
EW-13M372OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLFSWJpUUN3ME25OU44PSCwTR?=NYDSb5lyW0GQR1XS
HSC-2M33Ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjGNoxKSzVyPUm1Mlg6KG6PMXnTRW5ITVJ?
U031NILCZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfIWIRKSzVyPUm2Mlc{KG6PMmL2V2FPT0WU
EW-11NIHTNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3mflhKSzVyPUm2Mlg5KG6PNYfiS2dSW0GQR1XS
GAKM1LsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTl6LkmzJI5OMoXyV2FPT0WU
SK-OV-3MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPxZotKSzVyPUGwNE4xPyCwTR?=NHvq[IdUSU6JRWK=
OMC-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fxc2lEPTB;MUCwMlE5KG6PMoHDV2FPT0WU
TK10NFf4dYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTFyMD6yNUBvVQ>?MVjTRW5ITVJ?
EKVXM4PzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTFyMD62JI5OMmXpV2FPT0WU
Detroit562NFTSc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIm4c5dKSzVyPUGwNk4yPyCwTR?=M{\hXnNCVkeHUh?=
SF268MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHReXpKSzVyPUGwNk4{PCCwTR?=Mn;JV2FPT0WU
SNU-387NGi2VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFu4NGFKSzVyPUGwOE4yPyCwTR?=MXnTRW5ITVJ?
MDA-MB-231NHztT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkW4TWM2OD1zMEWuNFYhdk1?M4nvcHNCVkeHUh?=
NCI-H1563M{nMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTFyNT6xPEBvVQ>?NXnsVFdiW0GQR1XS
D-502MGNWjJOJdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFOxPWxKSzVyPUGwOU44KG6PMYTTRW5ITVJ?
A2780M3;pSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPOdHJxUUN3ME2xNFYvPDdibl2=MkDDV2FPT0WU
IA-LMMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoiwTWM2OD1zMEeuOVEhdk1?Mm\CV2FPT0WU
D-392MGMnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3uTWM2OD1zMEeuOVQhdk1?MVnTRW5ITVJ?
MS-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfGfJRFUUN3ME2xNFcvPzFibl2=NFvBT4tUSU6JRWK=
SW1990NXTTXoppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrUTWM2OD1zMEiuOVQhdk1?MlnrV2FPT0WU
HELMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVO3fIwzUUN3ME2xNFkvOjlibl2=MYnTRW5ITVJ?
SW1573M1zjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfweZRMUUN3ME2xNFkvOzFibl2=MlrNV2FPT0WU
SW1783MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPLemp7UUN3ME2xNVAvOjJibl2=Mn;OV2FPT0WU
COLO-680NM1nwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfJOphKSzVyPUGxNE44PiCwTR?=NXTzUYtPW0GQR1XS
NCI-N87NHT4cGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTFzMT6wOEBvVQ>?NF31b2RUSU6JRWK=
SK-MEL-28NFXOem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PiSmlEPTB;MUGxMlU2KG6PNWrSTGV{W0GQR1XS
BT-20NFnxZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HYOGlEPTB;MUGyMlAyKG6PMnzOV2FPT0WU
NCI-H1648NYS3T4xkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zneWlEPTB;MUGzJI5OMknSV2FPT0WU
no-11MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\WeYdKSzVyPUGxN{4zQCCwTR?=M2XlTnNCVkeHUh?=
MOLT-13NEHB[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4C1eWlEPTB;MUGzMlQ1KG6PMo\UV2FPT0WU
NCI-H2170M2HFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDTWnJZUUN3ME2xNVQvPTFibl2=MUXTRW5ITVJ?
HTC-C3MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTFzNj64OUBvVQ>?NX23Wm0zW0GQR1XS
LU-99AM{nRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnNdpNKSzVyPUGxO{4zOSCwTR?=NYXC[nhjW0GQR1XS
HCC2998MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\zOW9tUUN3ME2xNVcvQTJibl2=M3;5RnNCVkeHUh?=
NB13MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHPUHVEUUN3ME2xNVcvQTlibl2=NILBNIdUSU6JRWK=
GT3TKBMkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTFzOD6wPEBvVQ>?NHrvUo9USU6JRWK=
BT-549MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTvUIhbUUN3ME2xNVgvQTVibl2=MVvTRW5ITVJ?
NCI-H747MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLaTWM2OD1zMUmuN|Qhdk1?NHfncWFUSU6JRWK=
EW-1M3;aVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGD2OZRKSzVyPUGyNE4zKG6PNGnSW4NUSU6JRWK=
LB831-BLCMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\MeXFbUUN3ME2xNlAvPjNibl2=NX7EdoNLW0GQR1XS
NMC-G1MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXqTWM2OD1zMkGuNVEhdk1?MkLpV2FPT0WU
COLO-679MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTF{Mj6xOUBvVQ>?NXzER2JUW0GQR1XS
HL-60M4W2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Moi5TWM2OD1zMkOuNUBvVQ>?MYjTRW5ITVJ?
MKN7NX\BUndDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTF{Mz64N{BvVQ>?NYP4VWZmW0GQR1XS
RERF-LC-MSMn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTF{ND6zNUBvVQ>?M2[0e3NCVkeHUh?=
DMS-114NXPFWXo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDOTWM2OD1zMkWuNFkhdk1?MVjTRW5ITVJ?
HuP-T4M1vPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PVcGlEPTB;MUK2Mlk4KG6PMknZV2FPT0WU
HCC2157MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYP5N2xlUUN3ME2xNlcvPSCwTR?=MmXGV2FPT0WU
SKG-IIIaMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrXWHRKSzVyPUGyPE45KG6PNHvtfFdUSU6JRWK=
HCT-116NWX4S45lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3rdVBbUUN3ME2xN|AvPjRibl2=MYXTRW5ITVJ?
BB30-HNCMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkL1TWM2OD1zM{CuO|ghdk1?NVfBV|MyW0GQR1XS
KYSE-270NX60OZdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPjfIdmUUN3ME2xN|AvQDhibl2=NH7Db5hUSU6JRWK=
MFM-223MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LxUmlEPTB;MUOxMlUyKG6PNUPSRZB7W0GQR1XS
NH-12NWfjNGhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nucGlEPTB;MUOyMlk6KG6PM2jCUnNCVkeHUh?=
U-118-MGMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTF|Mz62NkBvVQ>?M2jL[HNCVkeHUh?=
ESS-1M1z3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3[3cGlEPTB;MUO1MlE5KG6PNF\1W5FUSU6JRWK=
D-247MGNFnqZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\VOGlEPTB;MUO1MlIyKG6PNIfvUpVUSU6JRWK=
IGROV-1NG\ORlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\3SWlEPTB;MUO1Mlc3KG6PNFT4NGVUSU6JRWK=
C-33-AM3TUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1W4[mlEPTB;MUO1Mlk4KG6PMXXTRW5ITVJ?
NCI-H1693NILwNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LtOmlEPTB;MUO2MlEzKG6PM3\MPHNCVkeHUh?=
MLMAMmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHrWGtoUUN3ME2xN|YvPThibl2=MWLTRW5ITVJ?
SK-N-ASM{DUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH32NJVKSzVyPUGzO{4yPyCwTR?=NWXoTVBzW0GQR1XS
NCI-H1755MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7mTWM2OD1zM{iuPFUhdk1?Mo[3V2FPT0WU
CHP-134NWPlSXJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLjTWM2OD1zM{muOVUhdk1?MX7TRW5ITVJ?
LS-513NFywOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTF2MD65NUBxVQ>?NXy4VHdIW0GQR1XS
TE-12NV\nXpFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTF2MD65N{BvVQ>?M2fLTXNCVkeHUh?=
KNS-42NHTVdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTF2ND6zJI5ONEnMZYpUSU6JRWK=
SJRH30NWX6c4lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHtemlKSzVyPUG0OE41PCCwTR?=MV\TRW5ITVJ?
NCI-H1092NVm4bXIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\OZ5NKSzVyPUG0OE42OiCwTR?=NGjoVGFUSU6JRWK=
H-EMC-SSNEfMR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHiydndKSzVyPUG0Ok45OSCwTR?=MXTTRW5ITVJ?
SK-MEL-3M4r2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvqRlZVUUN3ME2xOFcvPTVibl2=NEXHVm9USU6JRWK=
SK-N-FIMlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jZd2lEPTB;MUS3MlU6KG6PMVfTRW5ITVJ?
NCI-H2126Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTF2OD6xOUBvVQ>?M{jYd3NCVkeHUh?=
NCI-H1299MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zUNmlEPTB;MUWwMlIzKG6PM2TXcXNCVkeHUh?=
CFPAC-1MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLae3NKSzVyPUG1NE43PiCwTR?=NWXJT4FMW0GQR1XS
NCI-H661NEjr[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;BZmlEPTB;MUWxMlI3KG6PMUPTRW5ITVJ?
KYSE-70NUT4[FR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\NcmlEPTB;MUWxMlc6KG6PNHO2S49USU6JRWK=
SW900MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jISmlEPTB;MUW0MlY2KG6PNUfrenNEW0GQR1XS
Ca-SkiNF7Xc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDR[GpKSzVyPUG1Ok4{QSCwTR?=MYXTRW5ITVJ?
HPAF-IINV\VbZNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofLTWM2OD1zNU[uOFchdk1?NE\pTpBUSU6JRWK=
LB2518-MELNI\IXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonKTWM2OD1zNUeuNUBvVQ>?NETD[5dUSU6JRWK=
LC-2-adNWjBbXV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorvTWM2OD1zNUiuOlIhdk1?NF;lfXFUSU6JRWK=
HCC1806NXv0[YhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlO4TWM2OD1zNkeuPFghdk1?MkDmV2FPT0WU
UACC-62NFLKdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjYcY9kUUN3ME2xOlgvODlibl2=MXjTRW5ITVJ?
KM-H2NVXFXVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLHT2NKSzVyPUG3NE42QCCwTR?=M1jMSHNCVkeHUh?=
NCI-H2347MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTF5Mj63NkBvVQ>?MWPTRW5ITVJ?
SCC-15Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TCVmlEPTB;MUezMlY3KG6PNFT6bJhUSU6JRWK=
BB49-HNCNWnMS4RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPhXJRGUUN3ME2xO|MvQDFibl2=MVHTRW5ITVJ?
GMS-10NGO1XmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPob4tVUUN3ME2xO|MvQTRibl2=NH3xR|VUSU6JRWK=
NCI-H2052NXjEPVJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13Rd2lEPTB;MUe0Mlkhdk1?NUDWRo5NW0GQR1XS
SW626NFnxfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HYXmlEPTB;MUe2MlA3KG6PNXviVmxGW0GQR1XS
MDA-MB-415MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfK[4pUUUN3ME2xO|YvPjFibl2=MYDTRW5ITVJ?
Saos-2MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfKTmJKSzVyPUG3PU4{PSCwTR?=NYnnVXR6W0GQR1XS
DK-MGMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDyV25KSzVyPUG4NE4{KG6PNXXMNnh4W0GQR1XS
SNU-C2BM3PFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTF6MD63N{BvVQ>?NELjVm1USU6JRWK=
A427NFvP[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXWyZmExUUN3ME2xPFIvPTdibl2=Ml;sV2FPT0WU
KP-N-YSNWDmNYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTLTWM2OD1zOEWgcm0>NUDrUoxWW0GQR1XS
J82NVzmc4NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIraOZpKSzVyPUG4OU4yQCCwTR?=M1rweHNCVkeHUh?=
LS-411NM{nT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoOzTWM2OD1zOEeuNlghdk1?MVzTRW5ITVJ?
HCC1937Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPJTFdKSzVyPUG4O{41QSCwTR?=NXm3Z4p1W0GQR1XS
OE33NXzS[WVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWX6SYtKUUN3ME2xPFgvQTdibl2=M2DHPXNCVkeHUh?=
NB7Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTF6OT64PUBvVQ>?MUnTRW5ITVJ?
SW684NUH0UYxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTF7Nj6xN{BvVQ>?NF:zWYZUSU6JRWK=
HT-144NWrGZlNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzjTWM2OD1zOU[uNVUhdk1?NH\VV21USU6JRWK=
SK-MEL-30MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlflTWM2OD1zOU[uNkBvVQ>?MlLCV2FPT0WU
DBTRG-05MGMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3[wWGlEPTB;MUm4MlQ4KG6PM2XLZXNCVkeHUh?=
NCI-H1395M2LRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTF7OD64OUBvVQ>?NGDMU|RUSU6JRWK=
NCI-H2122MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3:yT2lEPTB;MkCwMlU6KG6PMlzvV2FPT0WU
no-10M2jnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vkNGlEPTB;MkCxMlA1KG6PMYDTRW5ITVJ?
SW48NV\YclBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTJyMT6zNUBvVQ>?MmrKV2FPT0WU
NCI-H1650M2Ky[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DRNGlEPTB;MkC0MlAyKG6PNYjLbpQxW0GQR1XS
MZ1-PCNX\rcIc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDwOVM5UUN3ME2yNFUvPThibl2=NUe2b5pkW0GQR1XS
U-266MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJyNT63PUBvVQ>?NYXZfVNRW0GQR1XS
CAS-1MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLwZodKSzVyPUKwO{41PCCwTR?=NV;L[|VoW0GQR1XS
AU565MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLqTVhKSzVyPUKxNk45OiCwTR?=NYL3V2p5W0GQR1XS
UACC-257NY\EdlJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfWd3dKSzVyPUKxN{46QSCwTR?=MlTrV2FPT0WU
CAL-27MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHGSY5KSzVyPUKxO{4xPSCwTR?=M2PZc3NCVkeHUh?=
NCI-H23MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XkdWlEPTB;MkG5MlM{KG6PNEX0[HNUSU6JRWK=
TE-6NUPVe4xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTJzOT62PEBvVQ>?M1HHNXNCVkeHUh?=
TGBC24TKBMo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJ{Mj6xO{BvVQ>?NG\a[HBUSU6JRWK=
TE-1M3TVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTJ{Mj64PEBvVQ>?M2nNN3NCVkeHUh?=
RCC10RGBNYLwb3NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTTeVI4UUN3ME2yNlQvOTlibl2=NUHqcphmW0GQR1XS
NCI-H596NH3nSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\iWWZKSzVyPUKyPE4zOiCwTR?=MkPVV2FPT0WU
SW954NHLz[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlL1TWM2OD1{M{OuPFMhdk1?Mm\3V2FPT0WU
NCI-H2087MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnKW24yUUN3ME2yN|QvPTFibl2=NF\LeGNUSU6JRWK=
SK-PN-DWM3LQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XlTmlEPTB;MkO1MlE6KG6PMlPqV2FPT0WU
KM12MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojOTWM2OD1{M{WuO{BvVQ>?MXfTRW5ITVJ?
BT-474M4PrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIOzVpVKSzVyPUKzOU44OyCwTR?=MYjTRW5ITVJ?
IST-MES1MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDvd2dyUUN3ME2yN|YvPTdibl2=MXLTRW5ITVJ?
HT-1197MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\USndtUUN3ME2yN|gvODlibl2=NVjWXXByW0GQR1XS
CAL-54MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTJ|OD60PUBvVQ>?M{GxbnNCVkeHUh?=
NB10MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTJ2MD6wOkBvVQ>?NVToU257W0GQR1XS
PANC-10-05MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULy[YN7UUN3ME2yOFUvPTZibl2=MXLTRW5ITVJ?
NCI-H522NXXm[IRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DsOWlEPTB;MkS4MlMyKG6PM{m5S3NCVkeHUh?=
A388MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTJ2OT64NkBvVQ>?MmjFV2FPT0WU
GOTOMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTlUo9KSzVyPUK1NE4zQSCwTR?=MlS1V2FPT0WU
KLEMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTJ3MT64O{BvVQ>?MVzTRW5ITVJ?
KYSE-520NWnyNYd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnK5TWM2OD1{NUKuPFYhdk1?NYPr[pdmW0GQR1XS
HCE-4Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTzbJhkUUN3ME2yOlIvPSCwTR?=NEn2Zm1USU6JRWK=
KURAMOCHINFLKfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XaNGlEPTB;Mk[1Mlkhdk1?MWjTRW5ITVJ?
HCC38MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLxPYxKSzVyPUK2Ok41QCCwTR?=M4\tTXNCVkeHUh?=
FADUMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTJ4Nj62N{BvVQ>?NX3oPZliW0GQR1XS
CW-2M{XObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTJ4OT65OkBvVQ>?MWHTRW5ITVJ?
L-428NIjMTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTJ5NT6xOUBvVQ>?MYjTRW5ITVJ?
HCC1569MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFS4OWhKSzVyPUK3OU45PCCwTR?=MW\TRW5ITVJ?
NCI-H810NUS0[ZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkG1TWM2OD1{N{iuN|Ehdk1?MXzTRW5ITVJ?
LB771-HNCNE\5ZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTJ6NT64OEBvVQ>?Mm\2V2FPT0WU
LCLC-103HMn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3STllwUUN3ME2yPFUvQTlibl2=NXrpO3FoW0GQR1XS
EFO-21NGPJZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTJ6Nz62PEBvVQ>?MlmxV2FPT0WU
CAL-72M1;0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LDWGlEPTB;MkmzMlE6KG6PMlr3V2FPT0WU
SCC-9NETWdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TtS2lEPTB;MkmzMlIzKG6PMkPIV2FPT0WU
COLO-829NHzOfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1P4WGlEPTB;Mkm2MlUhdk1?NXG2bZhUW0GQR1XS
U-87-MGMlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTNyMD63N{BvVQ>?MlXIV2FPT0WU
MZ7-melM{m3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXzVFhKSzVyPUOyN{44PiCwTR?=NFLhT45USU6JRWK=
NCI-H1770NGjZfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnCcpJKSzVyPUOyOk44PCCwTR?=MWPTRW5ITVJ?
ChaGo-K-1NYXsV4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX22bIZ{UUN3ME2zNlgvOSCwTR?=NHj3dFlUSU6JRWK=
SiHaNI\IT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLqWYllUUN3ME2zNlkvOjRibl2=NIX4TGRUSU6JRWK=
NCI-SNU-5M{fYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvDTWM2OD1|M{[uO|chdk1?NH3wNIpUSU6JRWK=
DJM-1NYDnSWp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnU[5pKSzVyPUO0NE4{OyCwTR?=M4HtTnNCVkeHUh?=
OE19M3nHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DnTGlEPTB;M{SwMlU{KG6PM33WcHNCVkeHUh?=
NCI-H1651MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH71SVVKSzVyPUO0OE4yQCCwTR?=MWDTRW5ITVJ?
COLO-792Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPMSG5TUUN3ME2zOVQvPDJibl2=M2fGVnNCVkeHUh?=
ACHNNEH3WZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTN3Nj63NUBvVQ>?MnzhV2FPT0WU
TH-3M1XsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{D2VmlEPTB;M{e5Mlk2KG6PMXHTRW5ITVJ?
HT-1376MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3v3VGlEPTB;M{i0Mlg5KG6PNW\tOm1yW0GQR1XS
RH-18M3X0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTN7ND63OEBvVQ>?MXPTRW5ITVJ?
NB6M4m1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknPTWM2OD1|OU[uOlYhdk1?M{Ts[XNCVkeHUh?=
COLO-320-HSRMnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\RTI5EUUN3ME20NFMvOzdibl2=MlH2V2FPT0WU
UACC-893M4PP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTRyNj60O{BvVQ>?MmrGV2FPT0WU
DSH1NF3YWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTRyNj65NUBvVQ>?NFn2bVVUSU6JRWK=
TE-10MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDWfIZKSzVyPUSwO{4xOSCwTR?=MkjlV2FPT0WU
HCC70M4ToW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzOdnFKSzVyPUSwPU4zOSCwTR?=MYDTRW5ITVJ?
TGBC11TKBMmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLHT4VNUUN3ME20NVAvOzNibl2=MV3TRW5ITVJ?
NCI-H727M3y2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;xTWM2OD12MUKuNVEhdk1?MUnTRW5ITVJ?
ALL-PONWH2VIU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTRzNT62PUBvVQ>?MYXTRW5ITVJ?
ABC-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jBcGlEPTB;NEKwMlQ2KG6PMUXTRW5ITVJ?
NCI-H69MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DhPGlEPTB;NEK2Mlc3KG6PM1frTnNCVkeHUh?=
GP5dNITlSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fne2lEPTB;NEO0MlQyKG6PMoO3V2FPT0WU
UMC-11MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfEWHVKSzVyPUS1PE4{PiCwTR?=MWDTRW5ITVJ?
RMG-INXXkfm96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHOcm1KSzVyPUS2O{42PiCwTR?=MVjTRW5ITVJ?
YAPCMoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLzR2NkUUN3ME20PVAvPiCwTR?=MlKxV2FPT0WU
LS-1034MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHiTWM2OD12OUGuNFYhdk1?MnXJV2FPT0WU
RCM-1MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DvVmlEPTB;NEm2MlY5KG6PM{XlfnNCVkeHUh?=
HCC1954M1Lob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LEcmlEPTB;NUGyMlUhdk1?M2nZOHNCVkeHUh?=
SK-MEL-24M4n3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\nZlVVUUN3ME21NVYvPTFibl2=MV7TRW5ITVJ?
NB12NIDvbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmKxTWM2OD13MkiuOFIhdk1?NHKybYNUSU6JRWK=
SW756Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTV3ND65OkBvVQ>?M1H5ZnNCVkeHUh?=
HCC1187NFzzS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jTUGlEPTB;NUe1Mlg{KG6PNX\KNFFGW0GQR1XS
NCI-H2342MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjpb4lKSzVyPUW5NE4{QSCwTR?=NWexRXZ6W0GQR1XS
NCI-H2291MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXRTWM2OD13OUiuN|Ehdk1?NH3l[nNUSU6JRWK=
OVCAR-3NHX0SIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHmTWM2OD13OUiuPVYhdk1?NVLFUpdtW0GQR1XS
MHH-NB-11NFHNdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TLNWlEPTB;NkK5MlAyKG6PMV7TRW5ITVJ?
SASMk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3T2TWlEPTB;NkWyMlY4KG6PNUPkSlJtW0GQR1XS
COLO-824M4n4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWf6fY1NUUN3ME22PFkvOzdibl2=M2OxbXNCVkeHUh?=
HCC1395MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DYV2lEPTB;Nkm4MlUhdk1?NV;OOmJmW0GQR1XS
COLO-668MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2joSGlEPTB;N{C2MlEhdk1?MnPIV2FPT0WU
NCI-H226NXvzd|ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTdyNz64JI5ONEXQPJVUSU6JRWK=
NB17NYDpXpNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULwTWpzUUN3ME23NlEvPzVibl2=Mle3V2FPT0WU
SW1463M{S1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPuTWM2OD15M{muNVkhdk1?NUXOem95W0GQR1XS
TGWM1HjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTd4MD6xOUBvVQ>?NX;PeolWW0GQR1XS
NCI-H526M4fadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvHXphKSzVyPUiyN{42OyCwTR?=NX3p[HpqW0GQR1XS
COR-L88NWXhcVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLGbItDUUN3ME24OFgvOTJibl2=MYLTRW5ITVJ?
NCI-H441MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTh7NT6yNkBvVQ>?MX3TRW5ITVJ?
NCI-H630MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTlzMj65OkBvVQ>?NHr0RVFUSU6JRWK=
Mo-TMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTl2Nz64PEBvVQ>?MULTRW5ITVJ?
JARNED2b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVG3b3c3UUN3ME25OVYvOjRibl2=NUDUcpBtW0GQR1XS
NCI-H1838NYPOdZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYWwWndYUUN3ME2xMlAzOzh6IN88US=>NELY[pZUSU6JRWK=
DoTc2-4510MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTFwMEezO|Yh|ryPMWPTRW5ITVJ?
MKN28NXLNdWc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVWyfHVqUUN3ME2xMlA6ODJ2IN88US=>M3rmcnNCVkeHUh?=
HuP-T3MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTFwMUG5NFUh|ryPNUXxT|gyW0GQR1XS
TE-9MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\KOIlKSzVyPUGuNVI6PzNizszNM4DYOnNCVkeHUh?=
NYNYrS[JR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrBXnFKSzVyPUGuNVY4QTJizszNM4fkcXNCVkeHUh?=
HT55M3fPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37sdGlEPTB;MT6zNVM1PCEQvF2=NGDZfIVUSU6JRWK=
SW837NIPNXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HVdGlEPTB;MT6zNlk4QCEQvF2=MXLTRW5ITVJ?
NCI-H2029NGjmcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPrTWM2OD1zLkSxO|kyKM7:TR?=NVXxd2NWW0GQR1XS
IST-SL1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTFwNESyOEDPxE1?NHLsc5FUSU6JRWK=
COLO-741MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoT2TWM2OD1zLkS5O|cyKM7:TR?=NXfOXGVkW0GQR1XS
LU-65MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17T[GlEPTB;MT62NlI1QSEQvF2=MmfiV2FPT0WU
NCI-H1304NHLYcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWf3eJFIUUN3ME2xMlY2PDl6IN88US=>M1j6XXNCVkeHUh?=
KARPAS-299MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTFwN{m0O|kh|ryPMmTKV2FPT0WU
NCI-H358M2rCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTFwOUW1NFMh|ryPNY\JXZVFW0GQR1XS
OAW-28MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTJwME[5NVkh|ryPNFP6VVdUSU6JRWK=
C8166NH3XblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fadWlEPTB;Mj62N|M6OiEQvF2=NFfFVHNUSU6JRWK=
COLO-678MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoS1TWM2OD1{LkizO|Y5KM7:TR?=Mmm2V2FPT0WU
SK-N-DZNEjtSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7mOYt3UUN3ME2yMlg3OzhzIN88US=>NWTmd2hOW0GQR1XS
NCI-H82NFzadYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PiNmlEPTB;Mj65NFM3QSEQvF2=MkfmV2FPT0WU
JVM-2M2rvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rZdWlEPTB;Mz6wN|E5QCEQvF2=NYj4UVJxW0GQR1XS
SW1116MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGS0NnVKSzVyPUOuNFU1OTFizszNMnX0V2FPT0WU
MDA-MB-453MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3PeZJKSzVyPUOuNVA1OzlizszNM4DMSXNCVkeHUh?=
Calu-6MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PsNmlEPTB;Mz6xPVk4KM7:TR?=M4r5UnNCVkeHUh?=
SHP-77Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljtTWM2OD1|LkWyPEDPxE1?MWfTRW5ITVJ?
Capan-2NHfGcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITNRmtKSzVyPUSuN|I2QDFizszNNEe1NVRUSU6JRWK=
SW948M3WzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rlOWlEPTB;ND63OFc4QSEQvF2=MX7TRW5ITVJ?
HDLM-2NUD5RZY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTVwMEe3NlUh|ryPNFvPT29USU6JRWK=
LAN-6NIPUVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTZwMkG0PVUh|ryPNYHOfVNlW0GQR1XS
LU-135NUj3bFRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ftUmlEPTB;Nj60N|A4PyEQvF2=M1PXc3NCVkeHUh?=
T84M3jL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGm5eFRKSzVyPU[uPVg3PCEQvF2=Mn;3V2FPT0WU
CAPAN-1MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTdwNkKyN|Mh|ryPNGG0UGZUSU6JRWK=
SW1417NFzxd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnGRolKSzVyPUeuPVE4OzFizszNMVrTRW5ITVJ?
BALL-1NYHyR3RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;lfGlEPTB;OD61NFQxQSEQvF2=MWXTRW5ITVJ?
HT-29NYfYNmFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTlwMEe1PVkh|ryPMmfMV2FPT0WU
C3AMl\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTIV244UUN3ME25Mlg5Ozl2IN88US=>M1;1cHNCVkeHUh?=
NCI-H1993NYTM[Wo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTFyLkWwPFEh|ryPMlfsV2FPT0WU
SK-MEL-1M1LTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13JZ2lEPTB;MUGuOlI5QSEQvF2=MVPTRW5ITVJ?
DU-145M2XYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\tdWlEPTB;MUSuOVA2OiEQvF2=M1vLcnNCVkeHUh?=
KP-N-YNM4rMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13mN2lEPTB;MUSuOVExOyEQvF2=NED5eoNUSU6JRWK=
CCRF-CEMNFOxPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnW1TWM2OD1zND63PFA6KM7:TR?=MknCV2FPT0WU
ZR-75-30M{DO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HDfWlEPTB;MU[uN|MxOyEQvF2=MnryV2FPT0WU
A673MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HafGlEPTB;MkCuOVUxPyEQvF2=M3PpfXNCVkeHUh?=
K-562NWrLbWx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDjTWM2OD1{OD60NVg{KM7:TR?=Mm\qV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro Protein Kinase, PI3K, and mTOR Assays PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH2-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.

Cell Assay:

[2]

Cell lines HCT116, DLD-1 and SW480 cells
Concentrations 0-1 μM
Incubation Time 48 hours
Method

The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 103 cells/well, DLD-1: 5.5 × 103 cells/well, SW480: 4.5 × 103 cells/well, DLD-1 PIK3CA mutant: 7 × 103 cells/well, and DLD-1 PIK3CA wild-type: 9 × 103 cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours.

Animal Study:

[1]

Animal Models Female Harlan athymic nude mice
Formulation NMP/polyethylene glycol 300 (10/90, v/v)
Dosages 45 mg/kg
Administration p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Maira SM, et al. Mol Cancer Ther, 2008, 7(7), 1851-1863.

[2] Roper J, et al. PLoS One, 2011, 6(9), e25132.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-25)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01856101 Terminated Carcinoma Transitional Cell Cliniques universitaires Saint-Luc- Université Catholique  ...more Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Novartis February 2013 Phase 2
NCT01717898 Terminated Castrate-resistant Prostate Cancer Patients. Charles Ryan|Novartis Pharmaceuticals|University of Calif  ...more Charles Ryan|Novartis Pharmaceuticals|University of California, San Francisco January 2013 Phase 1|Phase 2
NCT01658436 Completed Pancreatic Neuroendocrine Tumors (pNET) Novartis Pharmaceuticals|Novartis November 2012 Phase 2
NCT01628913 Terminated Pancreatic Neuroendocrine Tumors (pNET) Novartis Pharmaceuticals|Novartis October 2012 Phase 2
NCT01690871 Withdrawn Malignant PEComa (Perivascular Epithelioid Cell Tumors) Novartis Pharmaceuticals|Novartis September 2012 Phase 2

view more

Chemical Information

Download BEZ235 (NVP-BEZ235, Dactolisib) SDF
Molecular Weight (MW) 469.55
Formula

C30H23N5O

CAS No. 915019-65-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMF 18 mg/mL warming (38.33 mM)
DMSO 0.01 mg/mL (0.02 mM)
Water <1 mg/mL (<1 mM)
In vivo NMP+polyethylene glycol 300 (10+90, v+v) 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile

Customer Product Validation(8)


Click to enlarge
Rating
Source Cancer Res 2010 70, 4982-4994. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Detection of lipid kinase activities of PI3K p110α mutants
Cell Lines HEK293T cells
Concentrations
Incubation Time
Results "Evaluation of relative kinase activity of these mutants revealed that mutant P449T exhibited gain of function (>2-fold) compared with wild-type PI3K α (Fig. A). With regard to two hotspot mutants (E545K and H1047R), we examined the effect of NVP-BEZ235 and other PI3K inhibitors on their enzymatic activity and found no striking difference in their efficacies compared with wild-type p110α (Fig. B).

Click to enlarge
Rating
Source Clin Cancer Res 2010 16, 6029-6039. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Synergism studies, Immunoblot assays, Clonogenic assays
Cell Lines Melanoma cell
Concentrations 0.1-100 μM
Incubation Time 1-24 h
Results One of the proposed mechanisms of resistance to PI3KIs is mutation in the Ras-Raf pathway, which are found in more than half of melanomas. By ANOVA, no association was found between the IC50 values of NVP-BEZ235 and the presence or absence of B-Raf mutations (Fig. A). The targets of NVP-BEZ235, pAkt and pP70S6K, were both decreased with exposure to the drug in a time- and dose-dependent fashion, as shown in Figure B for YUVON and YUSIK cell lines. Clonogenicity was studied in YUVON and YUSIK cells with exposure to the dual PI3K/mTOR inhibitor. As shown in Figure C, NVP-BEZ235 effectively inhibits clonogenicity at low nanomolar concentrations.

Click to enlarge
Rating
Source Breast Cancer Res 2011 13, R52. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Immunofluorescence staining
Cell Lines MCF7 cells, IGF1R cells
Concentrations
Incubation Time
Results We investigated the effect of IGF-1 stimulation on MCF7/IGF-1R 4-OH-TAM resistance in a structurally and physiologically relevant context by use of a modified 3D culture. Both parental MCF7 (Figure a) and MCF7/IGF-1R cells (Figure b) were responsive to E2 or IGF-1 by forming acini on Matrigel, but the response was significantly larger in MCF7/IGF-1R cells with altered a cinar morphogenesis. inhibition of IGF -1R/ERK/Akt signaling by respective kinase inhibitors restored 4-OH-TAM sensitivity of MCF7/IGF-1R cells in 3D culture (Figure c).

Click to enlarge
Rating
Source Breast Cancer Res 2011 13:R52. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western blot, A sulforhodamine B ( SRB) colorimetric assay
Cell Lines MCF7 cells, GF-1R cells
Concentrations 0.01-10 μM
Incubation Time
Results IGF-1-stimulated proliferation was drastically restrained by BEZ235 at either 1 or 10 μM (Figure a).While IGF-1R and ERK signaling remained unaffected in response to IGF-1, the phosphorylation level of Akt was diminished with an increase in the dose of BEZ235, largely at 0.1 μM and entirely at 0.5 μM (Figure b). Likewise, the cell proliferation rate decreased correspondingly to Akt phosphorylation levels, significantly dropping at 0.1μM BEZ235 (Figure c)

Click to enlarge
Rating
Source Eur J Cancer 2010 46, 1111-1121. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method LanthaScreen assay
Cell Lines JFCR39 cell lines
Concentrations 0.016 μM
Incubation Time
Results As shown in Fig. A, NVP-BEZ235 and other inhibitors all inhibited mTOR in a dose-dependent manner. The IC50 values were calculated and are shown in Fig. B. NVP-BEZ235 inhibited mTOR potently, with IC50 value of 0.002 μM. In contrast, ZSTK474, GDC-0941 and LY294002 weakly inhibited mTOR, with IC50 values of 0.377, 0.413 and 3.86μM, respectively. To further demonstrate their selectivity for class I PI3K, the IC50 values of these inhibitors for mTOR were divided by their corresponding IC50s for class I PI3Ka, and the resulting ratios were plotted in Fig. C. Clearly, ZSTK474 and GDC-0941 revealed much higher selectivity for inhibiting class I PI3K than the other two inhibitors. In contrast, NVP-BEZ235 more potently inhibited the activity of mTOR than that of class I PI3K

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western blot
Cell Lines breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western blot
Cell Lines breast cancer cells
Concentrations 0-50 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source BEZ235 (NVP-BEZ235, Dactolisib) purchased from Selleck
Method Western Blotting
Cell Lines xenografts
Concentrations
Incubation Time
Results Phospholipase A2 group 4A (PLA2G4A) expression was increased after BEZ235 treatment in basal-like xenografts.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PI3K Products

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Recently Viewed Items

Tags: buy BEZ235 (NVP-BEZ235, Dactolisib) | BEZ235 (NVP-BEZ235, Dactolisib) supplier | purchase BEZ235 (NVP-BEZ235, Dactolisib) | BEZ235 (NVP-BEZ235, Dactolisib) cost | BEZ235 (NVP-BEZ235, Dactolisib) manufacturer | order BEZ235 (NVP-BEZ235, Dactolisib) | BEZ235 (NVP-BEZ235, Dactolisib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us